SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility

Molecular Cancer Therapeutics

Volumn 3, Issue 6, 2004, Pages 737-745

  Hjelmeland, Mark D ^a   Hjelmeland, Anita B ^a   Sathornsumetee, Sith ^a   Reese, Elizabeth D ^a   Herbstreith, Michael H ^a   Laping, Nicholas J ^b   Friedman, Henry S ^a   Bigner, Darell D ^a   Wang, Xiao Fan ^a   Rich, Jeremy N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ANTINEOPLASTIC AGENT; CELL PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOGENICITY; CELL MOTILITY; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ACTIVIN RECEPTORS, TYPE I; BENZAMIDES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DIOXOLES; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; PHOSPHORYLATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 4444341835     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998;40:51-5.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
3. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624-36.
4. Rich JN. The role of transforming growth factor-β in primary brain tumors. Front Biosci 2003;8:E245-60.
5. Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-β in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001;52:401-10.
6. 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992;148: 1404-10.
7. 1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol 1997;56:435-9.
8. Kjellman C, Olofsson SP, Hansson O, et al. Expression of TGF-β isoforms, TGF-β receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 2000;89:251-8.
9. Khalil N. TGF-β: from latent to active. Microbes Infect 1999;1:1255-63.
10. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin CH. Transforming growth factor-β1, -β2, and -β3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 1992;267:19482-8.
11. Chen RH, Derynck R. Homomeric interactions between type II transforming growth factor-β receptors. J Biol Chem 1994; 269:22868-74.
12. Ebner R, Chen RH, Shum L, et al. Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor. Science 1993;260: 1344-8.
13. Franzen P, ten Dijke P, Ichijo H, et al. Cloning of a TGF-β type I receptor that forms a heteromeric complex with the TGF-β type II receptor. Cell 1993;75:681-92.
14. Wrana JL, Attisano L, Carcamo J, et al. TGF-β signals through a heteromeric protein kinase receptor complex. Cell 1992;71:1003-14.
15. Chen Y, Lebrun JJ, Vale W. Regulation of transforming growth factor β- and activin-induced transcription by mammalian Mad proteins. Proc Natl Acad Sci USA 1996;93:12992-7.
16. Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-52.
17. Graff JM, Bansal A, Melton DA. Xenopus Mad proteins transduce distinct subsets of signals for the TGFβ superfamily. Cell 1996;85: 479-87.
18. Nakao A, Imamura T, Souchelnytskyi S, et al. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997; 16:5252-62.
19. Zhang Y, Fang XH, Wu RY, Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature 1996; 383:168-72.
20. Chang H-L, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R. Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 1993;53:4391-8.
21. 1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996;86:531-42.
22. Rich JN, Zhang M, Datto MB, Bigner DD, Wang XF. Transforming growth factor-β-mediated p15 INK4B induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem 1999;274:35053-8.
23. 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int J Cancer 1991;49: 129-39.
24. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 1996;93:2909-14.
25. Liau LM, Fakhrai H, Black KL. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-β antisense gene. Neurol Res 1998;20:742-7.
26. Jachimczak P, Hessdorfer B, Fabel-Schulte K, et al. Transforming growth factor-β-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 1996;65:332-7.
27. Stauder GM, Hau P, Bogdahn U, et al. A TGF-beta2 specific antisense oligonucleotide (AP12009) as continuous intratumoral treatment of recurrent high-grade glioma patients: A clinical phase I/II extention study. Proc Am Soc Clin Oncol 2003;22:109 (abstr 436).
28. Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74.
29. Laping NJ, Grygielko E, Mathur A, et al. Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol Pharmacol 2002;62:58-62.
30. Matsuyama S, Iwadate M, Kondo M, et al. SB-431542 and Gleevec inhibit transforming growth factor-β-induced proliferation of human osteosarcoma cells. Cancer Res 2003;63:7791-8.
31. Datto MB, Yu Y, Wang XF. Functional analysis of the transforming growth factor β responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 1995;270:28623-8.
32. Merzak A, McCrea S, Koocheckpour S, Pilkington GJ. Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor β1. Br J Cancer 1994;70:199-203.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
34. Sandstrom M, Johansson M, Sandstrom J, Bergenheim AT, Henriksson R. Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression. Int J Dev Neurosci 1999;17: 473-81.
35. Muracciole X, Romain S, Dufour H, et al. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 2002;52:592-8.
36. Hjortland GO, Bjornland K, Pettersen S, et al. Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1. Clin & Exp Metastasis 2003;20:301-9.
37. Isogai C, Laug WE, Shimada H, et al. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 2001;61:5587-94.
38. Hua X, Millar ZA, Wu G, Shi Y, Lodish HF. Specificity in transforming growth factor β-induced transcription of the plasminogen activator inhibitor-1 gene: interactions of promoter DNA, transcription factor muE3, and Smad proteins. Proc Natl Acad Sci USA 1999;96: 13130-5.
39. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
40. Roberts AB, Sporn MB. The transforming growth factor-β's. In: Sporn MB, Roberts AB, editors. Handbook of experimental pharmacology, peptide growth factors and their receptors. Heidelberg: Springer; 1990. p. 419-31.
41. Piek E, Westermark U, Kastemar M, et al. Expression of transforming-growth-factor (TGF)-β receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-β1. Int J Cancer 1999;80:756-63.
42. Brooks TD, Slomp J, Quax PH, et al. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. Clin & Exp Metastasis 2000;18:445-53.
43. Osmak M, Vrhovec I, Skrk J. Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1. J Neuro-oncol 1999;42: 95-102.
44. Shih SC, Claffey KP. Role of AP-1 and HIF-1 transcription factors in TGF-β activation of VEGF expression. Growth Factors 2001;19:19-34.
45. Yung WKA, Friedman H, Jackson E, et al. A phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. Proc Am Soc Clin Oncol 2003;22:99 (abstr 395).